ArticleJACS Au2022
Macrophage-Encapsulated Bioorthogonal Nanozymes for Targeting Cancer Cells.
Article in JACS Au, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Review
- Early Transition Metal-Based Antitumor Complexes.Chemistry, an Asian journal · 2026Review
- Chemical Surface Modification Tolerance of Primary and Immortalized Macrophages and Stem Cells.Chembiochem : a European journal of chemical biology · 2025Article
- Macrophage-centered therapy strategies: A promising weapon in cancer immunotherapy.Asian journal of pharmaceutical sciences · 2025Review
- Near-Infrared Light-Accelerated Bioorthogonal Drug Uncaging and Photothermal Ablation by Anisotropic Pd@Au Plasmonic Nanorods.Journal of the American Chemical Society · 2025Article
- Navigating the brain: Harnessing endogenous cellular hitchhiking for targeting neoplastic and neuroinflammatory diseases.Asian journal of pharmaceutical sciences · 2025Review
- Exploring New Bioorthogonal Catalysts: Scaffold Diversity in Catalysis for Chemical Biology.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Macrophage polarization: molecular mechanisms, disease implications, and targeted therapeutic strategies.Frontiers in immunology · 2025Review
- Development of Biocompatible Cu(I)-Microdevices for Bioorthogonal Uncaging and Click Reactions.Chemistry (Weinheim an der Bergstrasse, Germany) · 2024Article
- Modular Fabrication of Bioorthogonal Nanozymes for Biomedical Applications.Advanced materials (Deerfield Beach, Fla.) · 2024Review
- Polarization of macrophages to an anti-cancer phenotype throughChemical science · 2024Article
- Biomimetic and bioorthogonal nanozymes for biomedical applications.Nano convergence · 2023Review
- A narrative review: progress in transition metal-mediated bioorthogonal catalysis for the treatment of solid tumors.Translational cancer research · 2023Review
- Bioorthogonal nanozymes for breast cancer imaging and therapy.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- Inorganic nanoparticles as scaffolds for bioorthogonal catalysts.Advanced drug delivery reviews · 2023Review
- Immuno-photodynamic Therapy (IPDT): Organic Photosensitizers and Their Application in Cancer Ablation.JACS Au · 2023Review
- Dual-Bioorthogonal Catalysis by a Palladium Peptide Complex.Journal of medicinal chemistry · 2023Article
- Metal Coordination-Driven Supramolecular Nanozyme as an Effective Colorimetric Biosensor for Neurotransmitters and Organophosphorus Pesticides.Biosensors · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Macrophages migrate to tumor sites by following chemoattractant gradients secreted by tumor cells, providing a truly active targeting strategy for cancer therapy. However, macrophage-based delivery faces challenges of cargo loading, control of release, and effects of the payload on the macrophage vehicle. We present a strategy that employs bioorthogonal "nanozymes" featuring transition metal catalysts (TMCs) to provide intracellular "factories" for the conversion of prodyes and prodrugs into imaging agents and chemotherapeutics. These nanozymes solubilize and stabilize the TMCs by embedding them into self-assembled monolayer coating gold nanoparticles. Nanozymes delivered into macrophages were intracellularly localized and retained activity even after prolonged (72 h) incubation. Significantly, nanozyme-loaded macrophages maintained their inherent migratory ability toward tumor cell chemoattractants, efficiently killing cancer cells in cocultures. This work establishes the potential of nanozyme-loaded macrophages for tumor site activation of prodrugs, providing readily tunable dosages and delivery rates while minimizing off-target toxicity of chemotherapeutics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.